Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 115-119, March 2007

Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar

Department of Urology, University of Michigan, Ann Arbor, MI 48109-0330, USA

Received 10 January 2006; received in revised form 22 June 2006; accepted 14 July 2006.

Abstract 

Objective

Through examining our experience with renal mass surveillance, we hoped to determine factors suggestive of renal cell carcinoma.

Methods

We followed for at least 1 year 41 patients with 47 solid renal masses (mean diameter 2.0 cm, range 0.8–5). Mean surveillance duration was 29 months and was more than 2 years for 23 masses (49%).

Results

Overall mean increase in diameter was 0.27 cm/year, but 21 (45%) did not grow, and mean growth rate was 0.5 cm/year in the 26 that did grow. Of the masses, 14 have been treated, 33 continue to be followed, and pathology is known in 16 (34%). Growth was seen in all 6 known oncocytomas (mean 0.52 cm/year), 80% of the 10 biopsy proven renal cell carcinomas grew (mean 0.71 cm/year), but only 12 (39%) of the masses with unknown pathology (0.08 cm/year). There was no factor that distinguished oncocytomas from renal cell carcinomas. In 1 patient, a 3-cm mass that had not changed in size for 6 years doubled in size over 6 months, and metastatic disease developed.

Conclusions

Although growth of most renal masses is slow, some grow quickly, and delayed growth with metastases can occur. No factor distinguished renal cell carcinomas from oncocytomas. Surveillance for renal masses remains an option but must be rigorous and continuous, and is not without risk of progression.

Keywords: Kidney neoplasms, Computed tomography, Surveillance, Tissue biopsy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(06)00240-7

doi:10.1016/j.urolonc.2006.07.018

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 115-119, March 2007